Last reviewed · How we verify
NCT04876963
HOLT-ED: Holter-monitoring in End-stage Renal Disease
trial testing Holter-monitor in Kidney Failure, Chronic in 268 participants. Status unknown.
5 September 2024
Quick facts
| Lead sponsor | Rigshospitalet, Denmark |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 268 |
| Start date | 1 September 2021 |
| Primary completion | 5 September 2024 |
| Estimated completion | 5 September 2024 |
| Sites | 3 locations across Denmark |
Drugs / interventions tested
- Holter-monitor
Conditions studied
- Kidney Failure, Chronic — all drugs for Kidney Failure, Chronic →
- Arrhythmias, Cardiac — all drugs for Arrhythmias, Cardiac →
- Heart Diseases — all drugs for Heart Diseases →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Sponsor
Rigshospitalet, Denmark
Who can join
18 and older, any sex, with Kidney Failure, Chronic or Arrhythmias, Cardiac. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this prospective cohort study is to assess arrhythmia burden and glycemic variability in a multicenter cohort of patients with end-stage renal disease using a sufficient observation period in order to identify arrhythmia burden and type and characterize associations with patient characteristics and dialysis treatment, glycemic variability and subsequent risk of adverse outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04876963
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Failure, Chronic
Currently open trials in the same condition.
- NCT06903559 — Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients · Phase 1, PHASE2 · recruiting
- NCT06438445 — Effects of Royal Jelly Supplementation in Chronic Kidney Disease · NA · recruiting
- NCT06288451 — DePTH: De-emphasize PTH · Phase 2 · active not recruiting
- NCT05968391 — Acetoacetate and Acetate Metabolism in Patients With Chronic Kidney Failure.(RENO-TEP) · recruiting
- NCT06314503 — First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients · NA · recruiting
Other Rigshospitalet, Denmark trials
Trials by the same sponsor.
- NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
- NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
- NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
- NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
- NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04876963 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
- Last refreshed: 26 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04876963.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing